SWELL (SWELL) 24-hour volatility reaches 61.3%: trading volume surges with intense price fluctuations
Bitget Pulse2026/05/10 15:28Brief Summary of Volatility
In the past 24 hours, the price of SWELL surged from a low of $0.0124 to a high of $0.02, currently quoted at $0.01639, with an amplitude reaching 61.3%. Trading volume significantly expanded to about $1,737,000, indicating higher than usual activity.
Analysis of Reasons for the Abnormal Movement
• No official announcements, mainstream news, or major on-chain events (such as whale large transfers) were observed within 24 hours.
• Trading volume soared to over $1.73 million, directly amplifying price fluctuations, possibly due to short-term buying activity on centralized exchanges such as Coinbase.
Market Opinions and Outlook
The prevailing sentiment in the community (such as on X platform) is short-term speculative excitement, focusing on the "volume rip" caused by massive transactions. However, warnings are being raised about the formation of top wicks and potential exhaustion. Analysts highlight thin liquidity and heightened volatility, suggesting a high risk of short-term pullback.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Qualcomm (QCOM.US) Snapdragon Summit Preview: 2nm Dual-Chip Debuts, AI Diversification Narrative Faces Key Verification
Qualcomm is scheduled to hold its annual Snapdragon Summit in Maui, Hawaii, from September 22 to 24 local time.
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash
